ENLIGHTED: Padeliporfin VTP Offers High CR Rate in Low-Grade UTUC

4 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Vitaly Margulis, MD, UT Southwestern Medical Center, walks through the ENLIGHTED trial interim analysis, which provides efficacy and safety data for padeliporfin vascular targeted photodynamic therapy in the treatment of low-grade upper tract urothelial cancer.

He considers how padeliporfin VTP performed in terms of disease-specific efficacy endpoints like complete response rate and durability of response.
Category
Oncology
Be the first to comment

Up Next